Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Filters
Results by year
Table representation of search results timeline featuring number of search results per year.
Year | Number of Results |
---|---|
2022 | 5 |
2023 | 1 |
2024 | 1 |
Search Results
7 results
Results by year
Filters applied: . Clear all
Page 1
Clinical Consequences and Functional Impact of the Rare S737F CFTR Variant and Its Responsiveness to CFTR Modulators.
Int J Mol Sci. 2023 Mar 31;24(7):6576. doi: 10.3390/ijms24076576.
Int J Mol Sci. 2023.
PMID: 37047546
Free PMC article.
Virtual Drug Repositioning as a Tool to Identify Natural Small Molecules That Synergize with Lumacaftor in F508del-CFTR Binding and Rescuing.
Fossa P, Uggeri M, Orro A, Urbinati C, Rondina A, Milanesi M, Pedemonte N, Pesce E, Padoan R, Ford RC, Meng X, Rusnati M, D'Ursi P.
Fossa P, et al.
Int J Mol Sci. 2022 Oct 14;23(20):12274. doi: 10.3390/ijms232012274.
Int J Mol Sci. 2022.
PMID: 36293130
Free PMC article.
Item in Clipboard
Nasal epithelial cells as a gold-standard predictive model for personalized medicine in cystic fibrosis.
Pedemonte N.
Pedemonte N.
J Physiol. 2022 Mar;600(6):1285-1286. doi: 10.1113/JP282586. Epub 2022 Jan 31.
J Physiol. 2022.
PMID: 35038767
Free article.
No abstract available.
Item in Clipboard
Journey on VX-809-Based Hybrid Derivatives towards Drug-like F508del-CFTR Correctors: From Molecular Modeling to Chemical Synthesis and Biological Assays.
Parodi A, Righetti G, Pesce E, Salis A, Tomati V, Pastorino C, Tasso B, Benvenuti M, Damonte G, Pedemonte N, Cichero E, Millo E.
Parodi A, et al.
Pharmaceuticals (Basel). 2022 Feb 23;15(3):274. doi: 10.3390/ph15030274.
Pharmaceuticals (Basel). 2022.
PMID: 35337072
Free PMC article.
Item in Clipboard
The L467F-F508del Complex Allele Hampers Pharmacological Rescue of Mutant CFTR by Elexacaftor/Tezacaftor/Ivacaftor in Cystic Fibrosis Patients: The Value of the Ex Vivo Nasal Epithelial Model to Address Non-Responders to CFTR-Modulating Drugs.
Sondo E, Cresta F, Pastorino C, Tomati V, Capurro V, Pesce E, Lena M, Iacomino M, Baffico AM, Coviello D, Bandiera T, Zara F, Galietta LJV, Bocciardi R, Castellani C, Pedemonte N.
Sondo E, et al.
Int J Mol Sci. 2022 Mar 15;23(6):3175. doi: 10.3390/ijms23063175.
Int J Mol Sci. 2022.
PMID: 35328596
Free PMC article.
Item in Clipboard
Targeting the E1 ubiquitin-activating enzyme (UBA1) improves elexacaftor/tezacaftor/ivacaftor efficacy towards F508del and rare misfolded CFTR mutants.
Borgo C, D'Amore C, Capurro V, Tomati V, Sondo E, Cresta F, Castellani C, Pedemonte N, Salvi M.
Borgo C, et al.
Cell Mol Life Sci. 2022 Mar 16;79(4):192. doi: 10.1007/s00018-022-04215-3.
Cell Mol Life Sci. 2022.
PMID: 35292885
Free PMC article.
Item in Clipboard
SUMOylation Inhibition Enhances Protein Transcription under CMV Promoter: A Lesson from a Study with the F508del-CFTR Mutant.
Borgo C, D'Amore C, Capurro V, Tomati V, Pedemonte N, Bosello Travain V, Salvi M.
Borgo C, et al.
Int J Mol Sci. 2024 Feb 15;25(4):2302. doi: 10.3390/ijms25042302.
Int J Mol Sci. 2024.
PMID: 38396982
Free PMC article.
Item in Clipboard
Cite
Cite